Abstract:Background Trimethylamine N‐oxide (TMAO) contributes to cardiovascular disease through its prothrombotic, proatherothrombotic, and proinflammatory effects. We aimed to evaluate whether residual risk of recurrent stroke of TMAO and its precursor choline remain among patients who received dual‐antiplatelet therapy and intensive lipid‐lowering therapy and with a low inflammation level (high‐sensitivity C‐reactive protein <2 mg/L on admission). Methods and Results Patients with ischemic stroke or transient ischemic attack were enrolled from the CNSR‐III (Third China National Stroke Registry) in China. Plasma TMAO and choline concentrations at baseline were measured in 9793 participants using liquid chromatography–mass spectrometry. The primary outcome was a new stroke within 1 year. Multivariable‐adjusted hazard ratios were calculated using Cox regression models to investigate the associations of TMAO and choline with stroke recurrence. Among all patients, elevated TMAO and choline levels were associated with an increased risk of recurrent stroke (adjusted hazard ratios, 1.28 [95% CI, 1.12–1.45]; and 1.50 [95% CI, 1.32–1.71], respectively). Moreover, elevated TMAO and choline levels were associated with an increased risk of recurrent stroke among patients who received dual‐antiplatelet therapy (1.65 [95% CI, 1.28–2.13]; and 1.70 [95% CI, 1.32–2.19], respectively), intensive lipid‐lowering therapy (1.49 [95% CI, 1.15–1.94]; and 1.49 [95% CI, 1.15–1.92], respectively), with high‐sensitivity C‐reactive protein <2 mg/L (1.39 [95% CI, 1.14–1.69]; and 1.88 [95% CI, 1.53–2.30], respectively), and concurrently received dual‐antiplatelet therapy, intensive lipid‐lowering therapy and with high‐sensitivity C‐reactive protein <2 mg/L (3.57 [95% CI, 1.73–7.38]; and 2.19 [95% CI, 1.16–4.16], respectively). Conclusions TMAO and choline were risk factors for recurrent stroke independent of dual‐antiplatelet therapy, intensive lipid‐lowering therapy at discharge, and low inflammation on admission. Nonstandard Abbreviations and Acronyms CHANCE Clopidogrel in High‐Risk Patients With Acute Nondisabling Cerebrovascular Events CNSR‐III The Third China National Stroke Registry DAPT dual‐antiplatelet therapy ILT intensive lipid‐lowering therapy LoDoCo Low Dose Colchicine TMAO trimethylamine‐N‐oxide TOAST the Trial of ORG 10172 in Acute Stroke Treatment TST Treat Stroke to Target Clinical Perspective What Is New? Trimethylamine N‐oxide and choline were risk factors for recurrent stroke independent of dual‐antiplatelet therapy or intensive lipid‐lowering therapy at discharge and low inflammation on admission. What Are the Clinical Implications? Despite administration of evidence‐based secondary stroke prevention, trimethylamine N‐oxide and choline still contributed to residual risk of recurrent stroke, suggesting that intervention strategies to reduce trimethylamine N‐oxide and choline concentrations are needed in the future. The microbiota‐dependent metabolite trimethylamine‐N‐oxide (TMAO) has been both clinically and mechanistically linked to cardiovascular disease (CVD). 1 , 2 , 3 TMAO synthesis begins with dietary precursors, such as choline, that are abundant in various foods. 4 , 5 Mechanistic studies in both animals and humans have revealed that TMAO contributed to its detrimental effects on CVD, through its prothrombotic, proatherothrombotic, and proinflammatory effects. 4 , 6 , 7 , 8 , 9 , 10 , 11 Elevated plasma levels of TMAO and choline were linked with an increased risk of incident cardiovascular events in patients with ischemic stroke. 5 Recent clinical trials have addressed the above 3 targets of TMAO as the main therapeutic targets—residual -Abstract Truncated-

Relationship between elevated plasma trimethylamine N-oxide levels and increased stroke injury

Dynamic Changes and Prognostic Value of Gut Microbiota-Dependent Trimethylamine-N-Oxide in Acute Ischemic Stroke.

Elevated trimethylamine N-oxide related to ischemic brain lesions after carotid artery stenting.

Prognostic Value of Plasma Trimethylamine N-Oxide Levels in Patients with Acute Ischemic Stroke

TMAO as a Novel Predictor of Major Adverse Vascular Events and Recurrence in Patients with Large Artery Atherosclerotic Ischemic Stroke

Association of Trimethylamine N-Oxide and Its Precursor With Cerebral Small Vessel Imaging Markers

Trimethylamine N-Oxide and Stroke Recurrence Depends on Ischemic Stroke Subtypes.

Serum Trimethylamine N-Oxide Concentration is Positively Associated with First Stroke in Hypertensive Patients.

High Plasma Levels of Trimethylamine N-oxide Are Associated with Poor Outcome in Intracerebral Hemorrhage Patients

Trimethylamine N-Oxide Levels Are Associated with Severe Aortic Stenosis and Predict Long-Term Adverse Outcome

Gut microbial metabolite TMAO portends prognosis in acute ischemic stroke

Gut microbiota-derived metabolite trimethylamine-N-oxide and stroke outcome: a systematic review

Abstract 10334: The Association of Trimethylamine N-oxide (TMAO) with Findings of Vascular Brain Injury on Magnetic Resonance Imaging in the Cardiovascular Health Study (CHS)

Prognostic value of gut microbiota-derived trimethylamine N-oxide in patients with ischemic stroke: A meta-analysis

Analysis of correlation between oxidized low density lipoprotein and thrombus precursor protein with acute cerebral infarction

Effect of TMAO on the incidence and prognosis of cerebral infarction: a systematic review and meta-analysis

Residual Risk of Trimethylamine‐N‐Oxide and Choline for Stroke Recurrence in Patients With Intensive Secondary Therapy

Targeted Plasma Metabolomics Reveals Association of Acute Myocardial Infarction Risk with the Dynamic Balance Between Trimethylamine-N-oxide, Betaine, and Choline.

106Plasma Trimethylamine N-oxide is Associated with Culprit Plaque Characterization As Assessed by Optical Coherence Tomography in Patients with Acute Myocardial Infarction

Coronary atherosclerotic burden and trimethylamine N-oxide in non-ST-segment myocardial infarction patients: SZ-NSTEMI cohort

Trimethylamine-N-oxide: a potential biomarker and therapeutic target in ischemic stroke